Financial Data and Key Metrics Changes - Adjusted EBITDA for the full year reached approximately $18.6 million, up 83% from $10.2 million last year, exceeding guidance [4][12][29] - Consolidated total revenue increased by 66% in 2025 to $245.7 million, up from just over $148 million last year [13] - Net income for the year was $15.1 million, up 153% from $6 million in 2024, with diluted EPS improving 133% from $0.24 to $0.56 per share [28][29] Business Line Data and Key Metrics Changes - Revenue from procurement services totaled $197.5 million, up 68% from $117.5 million in 2024, with gross profit margins expanding from 6.7% to 7.7% [13][22] - Revenue from the systems integration segment increased 78% year-over-year to $40.3 million, with Q4 revenues rising from $7.9 million to $14.2 million [16][21] - Facilities management revenue totaled $7.9 million, down 1% from $8 million last year, but discrete project revenues in Q4 increased 263% to $2.5 million [15][21] Market Data and Key Metrics Changes - Customer adoption of AI is broadening, with 70%-80% of medium and large enterprises actively piloting or planning to implement AI in production workflows [7] - The market environment for AI demand is dynamic, with hyperscalers and large enterprises continuing to invest in accelerated computing and associated infrastructure [5][6] Company Strategy and Development Direction - The company aims to seize market share in AI rack integration and expand modular data center capabilities [9][33] - Strategic planning includes evaluating partnerships, acquisitions, and joint ventures to enhance capabilities and diversify revenue [33] - The company is focused on operational excellence and improving speed, quality, and time to value as key differentiators [34] Management's Comments on Operating Environment and Future Outlook - Management is optimistic about the business outlook for 2026, forecasting continued growth in earnings with adjusted EBIT expected in the $20-$22 million range [32] - The company acknowledges supply chain volatility and the timing of deal closings as factors in their conservative estimates [32] - Management emphasizes the importance of trusted partnerships as enterprises modernize and adopt AI technologies [34] Other Important Information - The company ended 2025 with $85.5 million of unrestricted cash, a $62.3 million increase from year-end 2024 [29] - Cash flow from operations increased significantly from $15.3 million in 2024 to over $30 million in 2025 [30] Q&A Session Summary Question: Can you give any more color on the amended agreement with your largest customer? - The agreement includes a term extension and adjustments for infrastructure investments, but minimum order volumes remain unchanged [38][41] Question: How should we be thinking about the amount of catch-up volume you saw this quarter? - Q4 rack volume almost exceeded Q1 through Q3, with expectations to double the business in 2026 [45] Question: What are you seeing in the U.S. federal business with the government shutdown resolved? - The procurement business is strong, with optimism about upcoming opportunities despite previous disruptions [49] Question: Can you talk about the memory chip shortage and its impact? - The company is somewhat insulated from the memory chip shortage due to strong supply chain management by their key partner [56] Question: How do your economics change as server racks get bigger? - The company is prepared for increased complexity and anticipates discussions on potential renegotiations as rack sizes grow [58]

Financial Data and Key Metrics Changes - Total revenues for 2025 were $180.5 million, representing a 12% year-over-year increase from $161 million in 2024 [5][17] - Adjusted EBITDA was $42 million, up 23% year-over-year from $34.1 million in 2024 [5][19] - Net income for 2025 was $20.2 million or $0.35 per diluted share, a 40% increase compared to $14.5 million or $0.25 per diluted share in 2024 [19] - Cash and cash equivalents at year-end 2025 were $75.5 million, down from $78.4 million in December 2024 [19] Business Line Data and Key Metrics Changes - Sales of KedRAB increased to approximately $54 million in 2025, exceeding the contract minimum commitment [10] - GLASSIA contributed total revenue of $35 million, with growth in both ex-U.S. markets and royalty income from Takeda [10] - Revenues from Cytogam declined due to increased usage of antivirals, with ongoing efforts to demonstrate its advantages through a new clinical study [11][12] Market Data and Key Metrics Changes - The company secured a $10 million-$14 million extension of an existing tender from Canadian Blood Services for various products, ensuring ongoing sales in Canada from Q2 2026 to Q1 2028 [17] - The distribution segment is expected to grow through the launch of additional biosimilars in Israel and expansion into the MENA region [9][14] Company Strategy and Development Direction - The company focuses on expanding its commercial product portfolio, including investment in FDA-approved specialty plasma-derived products and biosimilars [9] - Plans to ramp up plasma collection at new centers in Houston and San Antonio, with expected annual revenues of $8 million-$10 million at full capacity [15] - The company aims to secure new business development and M&A transactions to enhance its product portfolio and generate synergies [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet supply obligations despite geopolitical challenges in the Middle East [4] - The company affirmed its 2026 annual guidance of $200 million-$205 million in revenues and $50 million-$53 million in adjusted EBITDA, representing 13% and 23% growth, respectively [8] - Management emphasized the importance of Cytogam as additional protection for high-risk organ transplant recipients and the potential for increased usage following clinical studies [25] Other Important Information - A dividend of $0.25 per share, totaling approximately $14.4 million, was declared, reinforcing confidence in business prospects and liquidity for growth investments [6][7] Q&A Session Summary Question: CMV market and Cytogam usage - Management noted no changes in CMV management protocols but acknowledged increased access to antivirals affecting Cytogam usage [23][24] Question: M&A opportunities and dividend implications - Management confirmed that the dividend payment does not indicate a change in M&A opportunities, expressing optimism for securing transactions in 2026 [26] Question: Plasma collection growth margin benefits - Management expects growth margin benefits from proprietary plasma collection to start impacting gross profit in 2027 and beyond [27] Question: Plasma collection center ramp-up - Current ramp-up is at 30%-40%, with full capacity expected by the end of 2027 [31] Question: Timing for new biosimilars - New biosimilars are expected to launch around mid-2026, with sales ramping up based on market demand [32] Question: Dividend payment timing - The entire dividend will be paid out in the second quarter [40]

Verrica Pharmaceuticals (NasdaqGM:VRCA) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Company ParticipantsChris Chapman - Chief Commercial OfficerDavid Zawitz - Chief Operating OfficerJayson Rieger - President and CEOJohn Kirby - Interim Chief Financial OfficerKevin Gardner - Managing DirectorConference Call ParticipantsDennis Ding - AnalystDev Prasad - SVP, Biotech Equity Research AnalystKemp Dolliver - Director of Research and Senior AnalystRaghuram Selvaraju - Managing Director, Senior Healthcare Anal ...

TSS (NasdaqCM:TSSI) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Company ParticipantsAlex Foreman - Managing DirectorDanny Chism - CFODarryll Dewan - President and CEOJames Carbonara - VP of Investor and Public RelationsConference Call ParticipantsDavid Marsh - Equity Research AnalystMatthew Calitri - Equity Research Analyst of Infrastructure & Analytics and Security TechnologyOperatorGreetings, ladies and gentlemen, and welcome to the TSS, Inc. fourth quarter 2025 earnings results conference call. At t ...

Verrica Pharmaceuticals (NasdaqGM:VRCA) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Company ParticipantsChris Chapman - Chief Commercial OfficerDavid Zawitz - Chief Operating OfficerJayson Rieger - President and CEOJohn Kirby - Interim Chief Financial OfficerKevin Gardner - Managing DirectorConference Call ParticipantsDev Prasad - SVP, Biotech Equity Research AnalystGeorgia Bank - AnalystKemp Dolliver - Director of Research and Senior AnalystRaghuram Selvaraju - Managing Director, Senior Healthcare Ana ...

Financial Data and Key Metrics Changes - The company reported a 27% increase in revenue to $14.5 million for Q4 2025, with full-year revenue also growing 27% to $52.2 million compared to 2024 [4][18] - Gross profit for Q4 was $11.1 million, up from $8.5 million in the prior year, increasing gross margin to 76% [19] - Net income for Q4 was $2.9 million, compared to $1.5 million in the same period of 2024, with full-year net income of approximately $7.6 million compared to $2.9 million in 2024 [23] Business Line Data and Key Metrics Changes - A total of 95 Deep TMS systems were shipped during Q4, bringing the installed base to approximately 1,700 systems, a 26% increase year-over-year [4][18] - The book-to-bill ratio improved to 1.4x from 1.2x in the previous quarter, indicating strong demand [5] Market Data and Key Metrics Changes - Remaining performance obligations reached $70 million, representing a 43% growth from $49 million a year ago, reflecting strong demand and long-term commitments [5][24] - The company estimates it has penetrated less than 10% of the market for Deep TMS, indicating significant growth potential [7] Company Strategy and Development Direction - The company is focusing on expanding reimbursement coverage with payers across the U.S. to increase market share [8] - A strategic initiative is in place to secure minority equity investments in high-performing mental health providers, which is expected to facilitate faster access to interventional psychiatry modalities [14][15] - The company aims to develop a portfolio of data-driven technology-enabled neuromodulation solutions to serve more patients and settings [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum in the business and expects revenue in the range of $66 million to $68 million for 2026, representing a year-over-year growth rate of 27%-30% [24][25] - The company anticipates adjusted EBITDA of $12 million to $14 million for 2026, indicating expected growth of 86%-100% over 2025 [25] Other Important Information - The FDA granted label expansion for the Deep TMS system to treat adolescents aged 15 to 21 suffering from major depressive disorder, expanding the addressable patient population [9] - The company received a $2.5 million NIH grant for a study on Deep TMS for alcohol use disorder, highlighting ongoing clinical research efforts [12][13] Q&A Session Summary Question: Can you give us a better sense of the Q4 placements as far as units sold, units leased, and also any color regarding OCD placements? - Management reported that 95 systems were shipped during Q4, with more than 50% including H7 coils [26] Question: Can you talk about the Deep TMS 360 trial? - The trial is designed for addiction and neurology markets, with 10 centers actively recruiting patients for alcohol use disorder and three centers for Alzheimer's disease [28][29] Question: Was there any pricing change in 2025 or anticipated for 2026? - Management does not anticipate a decrease in average selling price and aims to optimize pricing based on the value provided [31]

Financial Data and Key Metrics Changes - In Q4 2025, the company delivered 780 homes, generating $260 million in revenue, a 9% decrease from the previous year [11] - The home closing gross margin was 19.9%, down from 25.5% in Q4 2024 [11] - Net income for Q4 was $17 million, or $0.39 per diluted share, compared to $30 million in the prior year [12] - For the full year 2025, the company delivered 2,908 homes, a 1% increase over 2024, with revenue of $971 million, essentially flat year-over-year [13][14] - Adjusted net income for Q4 was $12.8 million, down from $22.7 million in the same period last year [13] Business Line Data and Key Metrics Changes - The average sales price for homes was $334,000 in Q4 2025, down from $340,000 in 2024 [14] - Net new orders for the year were 2,726 homes, a 3% increase compared to 2024, with an average order price of $333,000 [15] - The company ended the year with 512 homes in backlog, valued at approximately $173 million [15] Market Data and Key Metrics Changes - The company experienced a 28% increase in active community count, reaching 100 communities compared to 78 at the end of 2024 [15] - Total controlled lots increased by 14% to approximately 22,300 lots, primarily through option contracts [16] Company Strategy and Development Direction - The company aims to grow volume and gain market share through targeted investments and a disciplined approach to home building [8][10] - The focus remains on building affordable homes in markets with strong population growth and job creation [9] - The company maintains a conservative balance sheet and prioritizes land ownership discipline [10] Management's Comments on Operating Environment and Future Outlook - Management noted that the housing market has been in a recessionary environment for about 18 months, driven by affordability pressures and higher mortgage rates [19] - The macroeconomic environment remains uncertain, with mixed signals from recent economic data and geopolitical developments [20] - The company expects closings in Q1 2026 to be between 575 and 625 homes, with average sales prices between $330,000 and $335,000 [21] Other Important Information - The company has seen an uptick in traffic and order activity relative to Q4 levels, although demand remains inconsistent [7] - The company is focused on maintaining pace and aligning sales absorption with production capacity [18] Q&A Session Summary Question: Sales pace and pricing trends in Q1 - Management indicated that sales pace followed traditional seasonal patterns, with an uptick in February and early March [24][26] Question: Trends across major markets - Management noted similarities in market pacing, with new markets expected to perform similarly once models are open [28] Question: Incentives and margin guidance for Q1 - Management explained that they leaned heavily into incentives in Q4, with a focus on maintaining sales pace while monitoring margins [34][35] Question: SG&A expenses and unusual items - Management clarified that SG&A expenses were impacted by new divisions not yet fully operational, leading to higher costs [45][46] Question: Land pricing trends - Management noted that while land costs are expected to increase in 2026, there are signs of a reset in pricing for new deals [56][57] Question: Spec count and inventory strategy - Management stated that specs are running about half of current inventory, with a focus on pre-sold homes to maximize value [65][66] Question: Land acquisition strategy - Management prefers finished lot purchases and is seeing softening opportunities in better locations [70][71]

Smith Douglas Homes (NYSE:SDHC) Q4 2025 Earnings call March 11, 2026 08:30 AM ET Company Participants Greg Bennett - President, Chairman, and CEO Joe Thomas - SVP of Accounting and Finance Mike Dahl - Managing Director Russ Devendorf - EVP and CFO Conference Call Participants Nikhil Kalra - Analyst Rafe Jadrosich - Senior Analyst Ryan Gilbert - Managing Director and Housing and Real Estate Services Analyst Operator Good morning. I would like to welcome everyone to the Smith Douglas Homes fourth quarter and ...

Financial Data and Key Metrics Changes - Consolidated fourth quarter 2025 revenue was $154.8 million, down from $163.3 million in the prior year, primarily due to softening customer demand [7] - Adjusted EBITDA for the fourth quarter was $2.3 million, compared to $0.9 million in the prior year, with adjusted EBITDA margins increasing to 1.5% from 0.6% [7][8] - Full year consolidated revenue was $649 million, down from $723.4 million in the prior year, with adjusted EBITDA at $17.8 million, down from $23.2 million [9][10] - Free cash flow for the full year was $33.7 million, up $21.5 million from last year, enabling a reduction in net debt by over $35 million [5][11] Business Line Data and Key Metrics Changes - Global Seating segment revenues decreased by 5.6% to $70.7 million in the fourth quarter, but adjusted operating income increased to $1.8 million [12] - Global Electrical Systems segment revenues increased by 12.7% to $49.7 million in the fourth quarter, with adjusted operating income rising to $0.9 million [13][14] - Trim Systems and Components revenues decreased by 22.5% to $34.4 million in the fourth quarter, resulting in an adjusted operating loss of $1.4 million [16][17] Market Data and Key Metrics Changes - The North American Class 8 truck market is experiencing a challenging demand environment, with a forecasted 4% increase in year-over-year volumes for 2026 [18] - The construction market is expected to grow in the low single-digit percentage range, driven by lower interest rates and fiscal stimulus initiatives [18] Company Strategy and Development Direction - The company is focusing on operational efficiency improvements and has announced a new contract with Zoox for autonomous vehicle components, indicating a strategic shift towards electric and autonomous vehicle markets [19][20] - The company aims to grow its Global Electrical Systems segment by more than 10% in 2026, supported by new business wins and increased capacity utilization [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about end market recovery and expects improved financial performance in 2026, with guidance for net sales between $660 million and $700 million [21][22] - The company anticipates generating positive free cash flow in 2026, which will be used to continue paying down debt and improving net leverage [21][22] Other Important Information - The company achieved a net leverage ratio of 4.1 times at the end of 2025, down from 4.7 times at the end of 2024 [10] - Interest expense for the fourth quarter was $4.2 million, up from $2.2 million in the prior year, driven by higher interest rates [8] Q&A Session Summary Question: Can you provide more color on the two key programs that started ramping in the third quarter? - Management confirmed that both programs are progressing as planned, with the Zoox program on track for volume production by the latter part of the second quarter [26][27] Question: What is the outlook for the aftermarket business? - The aftermarket business is expected to grow, driven by improved operational efficiencies and promotional initiatives [32][36] Question: What are the assumptions behind the guidance range for Adjusted EBITDA? - The guidance range reflects current macroeconomic trends and the anticipated recovery in Class 8 truck production, with expectations for significant drop-through of incremental top line [81][82]

Financial Data and Key Metrics Changes - Total revenues for 2025 were $180.5 million, representing a 12% year-over-year increase from $161 million in 2024 [5][17] - Adjusted EBITDA was $42 million, up 23% year-over-year from $34.1 million in 2024 [5][19] - Net income for 2025 was $20.2 million or $0.35 per diluted share, a 40% increase compared to $14.5 million or $0.25 per diluted share in 2024 [19] - Cash and cash equivalents at year-end 2025 were $75.5 million, down from $78.4 million in December 2024 [19] Business Line Data and Key Metrics Changes - Sales of KedRAB increased to approximately $54 million in 2025, exceeding the contract minimum commitment [10] - GLASSIA contributed total revenue of $35 million, with growth in both ex-U.S. markets and royalty income from Takeda [10] - Revenues from Cytogam declined due to increased usage of antivirals, with ongoing efforts to demonstrate its advantages through a new clinical study [11][12] Market Data and Key Metrics Changes - The company secured a $10 million-$14 million extension of an existing tender from Canadian Blood Services for various products, ensuring ongoing sales in Canada from Q2 2026 to Q1 2028 [17] - The company anticipates growth in its distribution segment through the launch of additional biosimilars in Israeli markets and expansion into the MENA region [9][14] Company Strategy and Development Direction - The company focuses on expanding its commercial product portfolio, including investment in FDA-approved specialty plasma-derived products and biosimilars [9] - Plans to ramp up plasma collection at new centers in Houston and San Antonio, with expected annual revenues of $8 million-$10 million per center at full capacity [15] - The company is pursuing new business development and M&A opportunities to enhance its product portfolio and generate synergies [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational and financial performance, despite geopolitical challenges in the Middle East [4] - The company affirmed its 2026 annual guidance of $200 million-$205 million in revenues and $50 million-$53 million in adjusted EBITDA, representing growth from 2025 results [8] - Management emphasized the importance of Cytogam in organ transplant protection and the potential for increased usage following clinical studies [25] Other Important Information - A dividend of $0.25 per share was declared, totaling approximately $14.4 million, reinforcing confidence in business prospects [6][7] - The company plans to continue investing in growth while maintaining dividend payments [26] Q&A Session Summary Question: CMV market and Cytogam usage - Management noted no changes in CMV management protocols but acknowledged increased access to antivirals affecting Cytogam usage [23][24] Question: M&A opportunities and dividend implications - Management confirmed that the dividend payment does not indicate a change in M&A opportunities, expressing optimism for securing transactions in 2026 [26] Question: Plasma collection growth margin benefits - Management expects growth margin benefits from plasma collection to start impacting gross profit in 2027 and beyond [27] Question: Plasma collection center ramp-up - Current ramp-up is at 30%-40%, with full capacity expected by the end of 2027 [31] Question: Timing for new biosimilars launch - New biosimilars are expected to launch around mid-2026, with sales ramping up based on market demand [32] Question: Dividend payment timing - The entire dividend will be paid in the second quarter [39]